Unaudited Financial Results For The Quarter Ended 30Th September, 2018 And Limited Review Reports Thereon.
In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Unaudited Financial Results for the quarter ended 30th September, 2018 (both Standalone and Consolidated) approved by the Board of Directors at its meeting held today i.e. 13th November, 2018 along with Limited Review Reports thereon.... Closure of Trading Window
This is to inform you that the Meeting of the Board of Directors of the Company will be held on Tuesday, 13th November, 2018 at Mumbai, to consider and approve the Unaudited Financial Results of the Company (both Standalone and Consolidated) for the quarter ended 30th September, 2018. Please note that as per the Insider Trading Code of the Company, the Trading Window for dealing in Company's shares will remain closed for the Company's insiders... Board Meeting Intimation for To Consider And Approve The Unaudited Financial Results Of The Company (Both Standalone And Consolidated) For The Quarter Ended 30Th September, 2018.
MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2018 ,inter alia, to consider and approve This is to inform you that the Meeting of the Board of Directors of the Company will be held on Tuesday, 13th November, 2018 at Mumbai, to consider and approve the Unaudited Financial Results of the Company (both Standalone and Consolidated) for the quarter ended 30th September, 2018.... Regulation 40 (9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Regulation 40 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. With reference to above captioned subject, please find enclosed half yearly Compliance Certificate pursuant to Regulation 40 (9) of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. This information pertains to half year ended September 30, 2018. Shareholding for the Period Ended September 30, 2018
Marksans Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2018. For more details, kindly Click here Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. All activities in relation to both physical and electronic share transfer facility are maintained by Marksans Pharma Limited's Registrar & Share Transfer Agent M/s. Bigshare Services Pvt. Ltd. Statement Of Investor Complaints For The Quarter Ended September 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Harshavardhan PanigrahiDesignation :- Company Secretary and Compliance Officer Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Marksans Pharma Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Details of Voting Results of the 24th Annual General Meeting of Marksans Pharma Limited Shareholder Meeting / Postal Ballot-Outcome of AGM
Outcome of the 26th Annual General Meeting held on Thursday, 27th September, 2018.